90 days suspension ipinataw sa solon dahil sa umano'y maanomalyang gamot | Bandera

90 days suspension ipinataw sa solon dahil sa umano’y maanomalyang gamot

Leifbilly Begas - December 17, 2018 - 03:23 PM

SINUSPINDE ng Sandiganbayan First Division si Samar Rep. Milagrosa Tan kaugnay ng kasong graft na kinakaharap nito dahil sa maanomalyang pagbili ng mga gamot.

Inatasan ng korte si House Speaker Gloria Macapagal Arroyo at Local Government Sec. Eduardo Año na ipatupad ang 90 araw na suspensyon laban kay Tan.

Kasamang nasuspendi ni Tan sina provincial treasurer Bienvenido Sabanecio Jr., provincial general service office officer-in-charge Arial Yboa, at supply officer George Abrina.

“Indeed, it is mandatory for the court to immediately issue the suspension order upon a proper determination of the validity of the information. Section 13 unequivocally mandates the suspension of a public official from office pending a criminal prosecution,” saad ng korte.

Maanomalya umano ang naging pagbili ng gamot ng provincial government noong siya pa ang gubernador ng lalawigan noong 2007.

Ang mga gamot at dental supplies ay binili sa Zybermed Medi Pharma na pagmamay-ari ni Roselyn Larce mula Marso 28 hanggang Agosto 21, 2007.

Ang Zybermed ay nakabase sa Pasig at walang lisensya na mag-operate sa Catbalogan City.

Ayon sa Commission on Audit “unnecessary and non-responsive to the exigencies of the service” ang ginawa ng probinsyang pagbili ng mga gamot.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Bandera. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

No tags found for this post.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

What's trending